In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.
The (NZB X NZW)F1 mouse is recognized as an important animal model of the human disease systemic lupus erythematosus (SLE). Groups of NZB/W F1 mice were treated either with IFN-gamma or with PBS. The results demonstrate that IFN-treated animals have accelerated development of fatal immune complex glomerulonephritis relative to age-matched controls. On the other hand, administration of mAbs specific for IFN-gamma to such mice from 4 to 7 mo of age resulted in significant remission. Development of both proteinuria and anti-DNA antibodies were delayed and survival at 11 mo was increased from less than 20% to 95% in treated mice relative to controls (p less than or equal to 0.001). These findings may have therapeutic implications for the treatment of SLE.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases; D004247:DNA / Q000276:immunology; D004195:Disease Models, Animal; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology*; D008181:Lupus Nephritis / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008814:Mice, Inbred NZB
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007371:Interferon-gamma; D004247:DNA